We are live on ! Find out more
PVLA

Palvella Therapeutics

25 hedge funds and large institutions have $10.1M invested in Palvella Therapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

182% more capital invested

Capital invested by funds: $3.58M → $10.1M (+$6.51M)

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

19% more funds holding

Funds holding: 2125 (+4)

17.37% more ownership

Funds ownership: 28.51%45.88% (+17%)

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

Holders
25
Holders Change
+4
Holders Change %
+19.05%
% of All Funds
0.36%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
3
Reduced
7
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$4.31M
ACM
2
ADAR1 Capital Management
Texas
$2.4M +$2.11M +144,641 New
BCM
3
BML Capital Management
Indiana
$699K +$616K +42,130 New
LCM
4
Lynx1 Capital Management
Puerto Rico
$621K -$88.6K -6,063 -14%
Renaissance Technologies
5
Renaissance Technologies
New York
$533K +$302K +20,700 +180%
CM
6
CM Management
Florida
$373K +$329K +22,500 New
FLSM
7
Frazier Life Sciences Management
California
$267K +$233K +15,942 New
BlackRock
8
BlackRock
New York
$215K -$541 -37 -0.3%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$201K +$19.8K +1,358 +13%
Citadel Advisors
10
Citadel Advisors
Florida
$196K +$171K +11,686 New
Vanguard Group
11
Vanguard Group
Pennsylvania
$190K
Acadian Asset Management
12
Acadian Asset Management
Massachusetts
$49K -$114K -7,814 -72%
Citigroup
13
Citigroup
New York
$18.5K
UBS Group
14
UBS Group
Switzerland
$5.77K -$20.1K -1,378 -80%
Group One Trading
15
Group One Trading
Illinois
$5.22K -$161 -11 -3%
US Bancorp
16
US Bancorp
Minnesota
$2.29K -$292 -20 -13%
Morgan Stanley
17
Morgan Stanley
New York
$1.51K +$132 +9 +11%
Barclays
18
Barclays
United Kingdom
$1.04K
Wells Fargo
19
Wells Fargo
California
$995
JP Morgan Chase
20
JP Morgan Chase
New York
$435 -$15 -1 -4%
TC
21
Truvestments Capital
Florida
$232 +$205 +14 New
Bank of America
22
Bank of America
North Carolina
$215
Osaic Holdings
23
Osaic Holdings
Arizona
$116
AF
24
Allworth Financial
California
$83
DB
25
Danske Bank
Denmark
$33 +$29 +2 New

PVLA Hedge Fund Activity: Q3 2024 in Review

25 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2024, worth a combined $10.1M — up 182% from $3.58M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new PVLA positions and 3 closed out — a net gain of 4 holders — while 3 added to existing stakes and 7 trimmed.

The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $2.11M. The largest seller was Acadian Asset Management, cutting an estimated $114K.

  • 25 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2024, up from 21 in Q2 2024.
  • Funds reported $10.1M of Palvella Therapeutics stock for Q3 2024, up 182% quarter-over-quarter.
  • 7 funds opened new Palvella Therapeutics positions in Q3 2024 and 3 closed out, a net change of +4 holders.
  • The largest Palvella Therapeutics buyer in Q3 2024 was ADAR1 Capital Management, an estimated $2.11M added.
  • The largest Palvella Therapeutics seller in Q3 2024 was Acadian Asset Management, an estimated $114K sold.

Based on aggregated 13F filings for Q3 2024.